Close
CDMO Safety Testing 2026
Novotech

German pharma benefiting from a Brexit boost?

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Quantum Machine Learning in Pharma Research Growth

The convergence of artificial intelligence and quantum processing is opening new avenues for rapid discovery and innovation within the life sciences. By utilizing advanced mathematical models that operate across multi-dimensional datasets, researchers can now identify complex biological patterns and predict molecular behaviors with a speed that surpasses traditional computational methods. This transformation is accelerating the development of novel therapies and providing deeper insights into disease mechanisms, fundamentally altering the trajectory of pharmaceutical research and development.

Quantum Sensors Enabling Advanced Drug Diagnostics

The landscape of medical diagnostics is being reshaped by the introduction of sensing technologies that operate with atomic-level sensitivity. By providing high-fidelity measurements and real-time data, these tools allow for the detection of subtle biological changes and chemical markers that were previously invisible to conventional equipment. This advancement is enhancing the precision of drug testing and clinical monitoring, leading to earlier disease detection and more effective therapeutic interventions across the global healthcare spectrum.

Quantum Computing Optimizing Pharma Supply Chains

The global distribution of pharmaceutical products is facing unprecedented challenges that demand a new level of logistical precision and resilience. By utilizing advanced analytical models, companies can now navigate complex international networks with greater efficiency, ensuring that temperature-sensitive medicines and life-saving therapies reach their destinations without delay. This evolution toward a more intelligent and responsive supply chain is critical for maintaining public health and responding effectively to emerging medical needs on a global scale.
- Advertisement -

Research conducted by CPhI Worldwide, the world’s largest pharmaceutical event (organised by Informa Markets and held at Messe Frankfurt, November 5-7), ranks Germany as Europe’s preeminent pharma industry. The data was drawn from the CPhI Annual Report and includes opinions from over 350 international pharma companies.

The ‘CPhI Pharma Index’ is the only annually produced perception ranking of the world’s top performing countries. It provides vital insights into the world’s leading pharma economies across all attributes, and indicates which markets have the greatest business prospects and growth potential.

The results see Germany consolidate its status as an elite pharmaceutical market, finishing ahead of its European rivals in API Manufacturing (7.88), competitiveness (6.48), innovation (7.49) finished product manufacturing (8.02), and growth potential (6.92).

CPhI Worldwide, which brings every stage of the pharmaceutical supply chain together – from ingredients and finished formulations to machinery, packaging, outsourcing and biopharmaceuticals – is widely used as a barometer of pharma’s overall strength and growth potential. This year, the event is expected to welcome over 45,000 attendees and 2,500 exhibitors, with nearly all major pharma countries registering a positive outlook for 2019 and 2020. Significantly, the outlook for Germany amongst both its domestic and international executives is particularly strong – improving its score across all metrics since 2018.

One of the most notable trends is the sudden rise in anticipated growth potential for Germany in 2019/2020, increasing by 11% from 2018. The research’s authors attribute the shifting European outlook over the last couple of years to wider macro changes, as well as the continued strength of European pharma. Germany is perceived to be reaping a ‘Brexit boost’ in its medium-term growth potential – with an equal drop in the UK scores directly correlating to the increases seen in Germany’s.

“It is no surprise that Germany has again emerged as a global pharmaceutical leader. However, the country has further increased its score, suggesting it has consolidated its position as Europe’s top pharma industry. There are a number of leading German manufacturers and service providers in the pharmaceutical industry in attendance at CPhI Worldwide this year, including BASF, B. Braun, Evonik, Vetter Pharma, AG, Wacker, Corden Pharma and Merck. In total, 223 German companies will be showcasing their strength to a global audience, with executives attending from over 150 countries ” said Orhan Caglayan, Brand Director at CPhI Worldwide.

The full CPhI Pharma Market Index will be made available later in the year within its 2019 Annual Industry Report.

Caglayan, added: “Significantly, in the event’s return to Frankfurt, the pharma industry in Germany is perceived as an international industry pioneer according to the latest CPhI Pharma Index. The country has the highest score in ‘API manufacturing quality’ globally, as well as the leading scores in Europe for ‘competitiveness’, ‘innovation’ and ‘finished product manufacturing’. Collectively, this points to extremely strong prospects for the German pharma industry in 2020.”

About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; and Finished Dosage Formulation for every aspect of the finished dosage supply chain. CPhI provides an online buyer and supplier directory at CPhI-Online.com. For more information visit https://www.cphi.com

About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.

The Informa Markets annual schedule of Pharmaceutical events include: CPhI, ICSE, P-MEC, FDF, InnoPack Worldwide, BioProduction (5-7, November, 2019 at the Messe in Frankfurt); CPhI & P-MEC India (26–28 November 2019 at the India Expo Mart, Greater Noida, Delhi NCR – Delhi, India); Pharmapack Europe (5-6 February, 2020 at the Paris Expo, Porte de Versailles – Paris, France); CPhI South East Asia (4-6 March, 2020 at the QSNCC – Bangkok, Thailand); CPhI Japan (16-18 March, 2020 at the Big Sight Exhibition Centre – Tokyo, Japan); CPhI North America (05 April – 07 May, 2020 at Pennsylvania Convention Centre – Philadelphia, USA); CPhI and P-MEC China (22-24 June, 2020 at SNIEC – Shanghai, China); CPhI Korea (26-28 August 2020), COEX – Seoul, Korea); CPhI Middle East & Africa (14-16 September, 2020 at the ADNEC – Abu Dhabi, United Arab Emirates)

Latest stories

Related stories

Quantum Machine Learning in Pharma Research Growth

The convergence of artificial intelligence and quantum processing is opening new avenues for rapid discovery and innovation within the life sciences. By utilizing advanced mathematical models that operate across multi-dimensional datasets, researchers can now identify complex biological patterns and predict molecular behaviors with a speed that surpasses traditional computational methods. This transformation is accelerating the development of novel therapies and providing deeper insights into disease mechanisms, fundamentally altering the trajectory of pharmaceutical research and development.

Quantum Sensors Enabling Advanced Drug Diagnostics

The landscape of medical diagnostics is being reshaped by the introduction of sensing technologies that operate with atomic-level sensitivity. By providing high-fidelity measurements and real-time data, these tools allow for the detection of subtle biological changes and chemical markers that were previously invisible to conventional equipment. This advancement is enhancing the precision of drug testing and clinical monitoring, leading to earlier disease detection and more effective therapeutic interventions across the global healthcare spectrum.

Quantum Computing Optimizing Pharma Supply Chains

The global distribution of pharmaceutical products is facing unprecedented challenges that demand a new level of logistical precision and resilience. By utilizing advanced analytical models, companies can now navigate complex international networks with greater efficiency, ensuring that temperature-sensitive medicines and life-saving therapies reach their destinations without delay. This evolution toward a more intelligent and responsive supply chain is critical for maintaining public health and responding effectively to emerging medical needs on a global scale.

Quantum security strengthening pharma data protection

Protecting sensitive patient information and proprietary research data is becoming a critical priority as the pharmaceutical industry navigates an increasingly complex digital landscape. By integrating advanced cryptographic methods and secure communication protocols, researchers can ensure the integrity of their clinical findings and the privacy of those involved in medical trials. This shift toward a more resilient digital infrastructure is essential for maintaining public trust and fostering global collaboration in the pursuit of life-saving therapeutic breakthroughs.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »